No such trend was reported among patients with end-stage kidney disease.

Patient outcomes, it seems, are not significantly impacted by this trend. 

Imaging-based PAD may provide value as a noninvasive alternative to right heart catheterization. 

Frailty measurements may still provide helpful information in other ways, of course. 

The blood-based biomarker was previously associated with worse acute coronary syndrome outcomes. What does it mean for TAVR patients?

Researchers presented their findings at TCT 2021, noting that TAVR and surgery had similar mortality rates after five years. 

The analysis, presented at TCT 2021, examined total costs after two years for more than 900 patients who underwent TAVR or SAVR.